Salinomycin Suppresses LRP6 Expression and Inhibits Both Wnt/β‐catenin and mTORC1 Signaling in Breast and Prostate Cancer Cells
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Emerging evidence indicates that activation of Wnt/β‐catenin signaling at the cell surface results in inhibition of glycogen synthase kinase 3β (GSK3β), leading to activation of mTORC1 signaling in cancer cells. The low density lipoprotein receptor‐related protein‐6 (LRP6) is an essential Wnt co‐receptor for Wnt/β‐catenin signaling. Salinomycin is a novel small molecule inhibitor of LRP6. In the present study, we found that LRP6 overexpression induced mTORC1 signaling activation in cancer cells, and that salinomycin was not only a potent Wnt/β‐catenin signaling inhibitor, but also a strong mTORC1 signaling antagonist in breast and prostate cancer cells. Mechanistically, salinomycin activated GSK3β in cancer cells. Moreover, salinomycin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/β‐catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity. Our results present novel mechanisms underlying salinomycin‐mediated cancer cell death. J. Cell. Biochem. 115: 1799–1807, 2014. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling
Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B. M., Delius, H., Hoppe, D., Stannek, P., Walter, C., et al. (2002) · Nature · doi:10.1038/nature756 · Cited by 1,038 · cited 1×
“Furthermore, the transmembrane proteins Kremen1 and Kremen2 can form a ternary complex with LRP6 and Dkk1 to induce rapid endocytosis and removal of LRP6 from the cell surface [Mao et al., 2002].”
BackgroundmTOR mediates Wnt-induced epidermal stem cell exhaustion and aging
Castilho, R. M., Squarize, C. H., Chodosh, L. A., Williams, B. O., & Gutkind, J. S. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.06.017 · Cited by 371 · cited 2×
“upregulation of mTORC1 signaling in cancer cells [Inoki et al., 2006; Fujishita et al., 2008; Castilho et al., 2009; Huang et al., 2009, 2012 Gao et al., 2010; Hagenmueller et al., 2010; Liu et al., 2012a; Kwan et al., 2013; Tahir et al., 2013; Valvezan et al., 2014].”
BackgroundInfluentialLu, W., Lin, C., Roberts, M. J., Waud, W. R., Piazza, G. A., & Li, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029290 · Cited by 230
Self-citationAverous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194 · cited 2×
“, 1999; Tetsu and McCormick, 1999] and mTORC1 signaling [Averous et al., 2008].”
Background
Cited by
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“Other old drugs like niclosamide to inhibit canonical Wnt signaling by promoting Fzd1 endocytosis,(404) celecoxib to induce the degradation of Tcf7,(405) and salinomycin to target LRP6.(406) Due to the functions of these old drugs for targeting Wnt/β-catenin signaling are still limitedly known, we will not continue to…”
BackgroundTherapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer
Cheng, X., Xu, X., Chen, D., Zhao, F., & Wang, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.082 · Cited by 417
WNT signalling in prostate cancer
Murillo-Garzón, V., & Kypta, R. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.144 · Cited by 361
WNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28
Le, P. N., McDermott, J. D., & Jimeno, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.005 · Cited by 253
Wnt/β-Catenin Signaling in Liver Cancers
Wang, W., Smits, R., Hao, H., & He, C. (2019) · Cancers · doi:10.3390/cancers11070926 · Cited by 143
Metadata
- Authors
- Lu, W., & Li, Y.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2014-08-13
- Volume
- 115
- Issue
- 10
- Pages
- 1799-1807
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W1575128272
- Cited by
- 109
- References
- 9
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.